The Australian Genomic Cancer Medicine Centre (AGCMC) and Molecular Screening and Therapeutics (MoST)

The AGCMC is a national network of eight cancers centres – one centre in every state and territory in Australia – that delivers the Australian Genomics Cancer Medicine Program. The program overseas precision oncology clinical trials and screening studies including: the Moecular Screening and Therapeutics (MoST) study; Genic Cancer Risk in the Young (RisC) study; and Surveillance study in Multi-Organ prone syndromes (SMOC+).

The primary AGCMC centres are:

  • Canberra Hospital, ACT
  • The Kinghorn Cancer Centre/Garvan Institute, NSW
  • Peter MacCallum Cancer Centre, VIC
  • Prince Alexandra Hospital, QLD
  • Royal Adelaide Hospital, SA
  • Royal Darwin Hospital, NT
  • Royal Hobart Hospital, TAS
  • Sir Charles Gairdner Hospital, WA

The MoST study performs genomic profiling to analyse the molecular characteristics of a patient’s tumour, and where possible, match them to a MoST therapeutic study (clinical trial) or other targeted therapy. Suitable patients include those aged 16 years and older with an advanced and/or metastatic sold or blood cancer with limited treatment options, and who are fit enough and willing to participate in a clinical trial. The study is targeting rare and less common cancers.

For more information visit: www.omico.com.au

The Australian Rare Cancer (ARC) Portal

The ARC Portal is a program under the AGCMC and supported by BioGrid Australia. It provides centralised (online) support for clinicians of patients including:

  • Access to rare cancer guidelines or evidence
  • Advice, in person or tele-consultations with national rare cancer experts
  • Molecular testing advice (including via AGCMC/MoST) or help with interpretation of existing reports.

The ARC Portal also allows Australian patients with rare cancers to enrol into the Stafford Fox Rare Cancer Program to allow their deidentified clinical data (and optionally biospecimens) to be used for research. All Australian researchers can access these resources for approved projects. By providing patients broader access to research we will accelerate our understanding of individual rare cancers and improved the feasibility of performing rare cancer research in Australia.

The ARC Portal can be found at: www.arcportal.org.au

The Stafford Fox Rare Cancer Program (SFRCP)

The Walter Eliza Hall Institute (WEHI) of Medical Research Stafford Fox Rare Cancer Program is a basic and translational research program for all rare cancers. It is based at the WEHI and is accessible through participating tertiary hospitals or via the ARC Portal. The SFRCP has internal research projects but can also help to facilitate external rare cancer research with access to clinically annotated rare cancer biospecimens.

Examples of projects supported by the SFRCP include:

  • Identification of novel drivers in patients with multiple rare cancers
  • Next generation sequencing of rare gynaecological malignancies
  • Understanding the distinct biology of gynaecological carcinosarcomas
  • Immunology and genomics of rare cancer super-responders
  • Novel therapies for high grade serous endometrial carcinomas
  • Uterine Leiomyosarcoma – genomics, pre-clinical models and therapeutics
  • Studies into ovarian sex-cord stromal tumours

https://www.wehi.edu.au/research-diseases/cancer/rare-cancers

ICCON: The inherited cancer connect partnership

Inherited cancer syndromes are individually rare but collectively important as they impose a significant impact on affected families and national health care costs. A collaborative approach is essential in order to understand these syndromes more effectively. ICCON is a Partnership of familial cancer centres within Australia that are working together to develop national infrastructure to better connect the inherited cancer community, including clinicians and researchers; identify people at risk of heritable cancers; and improve the accuracy of inherited cancer risk prediction and management strategies.

ICCON is being run out of national Familial Cancer Centres.